secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2026-06-12T20:05:45+00:00
Accession:  0001213900-26-068264
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Atara appoints Brian Cherry to board; annual meeting votes approve equity plan amendment
--------------------------------------------------------------------------------

- Brian Cherry appointed as Class I director, effective June 11, 2026; also joins Audit Committee.
- Initial RSU award of 24,000 shares vesting over 3 years; annual cash retainer $55,000.
- Stockholders elected AnhCo Nguyen and Nachi Subramanian to board at June 9 annual meeting.
- Advisory say-on-pay and amendment to 2024 Equity Incentive Plan (+400,000 shares) approved.
- Deloitte & Touche ratified as independent auditor for fiscal year ending December 31, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000121390026068264/0001213900-26-068264-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000121390026068264/ea0294561-8k_atara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-068264

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer